CIK 0001398733
- Non-accelerated filer
- Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208623253
- Phone
- +1 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- 4 Open-market sale Chief Innovation/Tech Officer sold 35,000 shares at $6.75 ($236,250)
- 4 Open-market sale Chief Innovation/Tech Officer sold 40,792 shares at $6.50 ($265,148)
- 3 Insider Initial Statement of Ownership
- 4 Gift CEO and President gave 2,000 shares (gift)
- 4 Open-market sale SVP-Chief Financial Officer sold 3,000 shares at $8.00 ($24,000)
- 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 94 shares (to pay taxes)
- 4 Shares withheld for taxes CEO and President gave up 148 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale CEO and President sold 50,000 shares at $5.11 ($255,310)
- 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 4,132 shares (to pay taxes)
- 4 Shares withheld for taxes CEO and President gave up 6,492 shares (to pay taxes)
- 4 Open-market sale Chief Innovation/Tech Officer sold 40,000 shares at $5.00 ($200,000)
- 4 Open-market sale Chief Innovation/Tech Officer sold 80,000 shares at an average $3.85 ($308,000)
- 4 Open-market sale Chief Innovation/Tech Officer sold 40,000 shares at $4.50 ($180,000)
- 4 Shares withheld for taxes CEO and President gave up 99 shares (to pay taxes)
Page 11 of 17 · 326 filings